TW201834698A - 抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物 - Google Patents

抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物 Download PDF

Info

Publication number: TW201834698A
Authority: TW; Taiwan
Prior art keywords: antibody; pharmaceutical composition; cancer; steroid; cells
Prior art date: 2017-03-03

Application number

TW107106953A

Other languages

English (en)

Chinese (zh)

Inventor

安永正浩

松村保広

眞鍋史乃

辻厚至

Original Assignee

國立研究開發法人國立癌症研究中心

日商凜研究所股份有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-03

Filing date

2018-03-02

Publication date

2018-10-01

2018-03-02 Application filed by 國立研究開發法人國立癌症研究中心, 日商凜研究所股份有限公司 filed Critical 國立研究開發法人國立癌症研究中心

2018-10-01 Publication of TW201834698A publication Critical patent/TW201834698A/zh

Links

229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 125
206010028980 Neoplasm Diseases 0.000 title claims abstract description 84
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 69
201000011510 cancer Diseases 0.000 title claims abstract description 57
239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 43
229940127089 cytotoxic agent Drugs 0.000 title claims abstract description 42
239000002254 cytotoxic agent Substances 0.000 title claims abstract description 39
206010061218 Inflammation Diseases 0.000 title claims abstract description 35
230000004054 inflammatory process Effects 0.000 title claims abstract description 35
229940125644 antibody drug Drugs 0.000 title description 4
238000011282 treatment Methods 0.000 claims abstract description 30
150000003431 steroids Chemical class 0.000 claims description 94
231100000599 cytotoxic agent Toxicity 0.000 claims description 35
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
201000010099 disease Diseases 0.000 claims description 32
239000000427 antigen Substances 0.000 claims description 29
108091007433 antigens Proteins 0.000 claims description 29
102000036639 antigens Human genes 0.000 claims description 29
239000012634 fragment Substances 0.000 claims description 29
IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 27
108010093470 monomethyl auristatin E Proteins 0.000 claims description 27
108010002586 Interleukin-7 Proteins 0.000 claims description 26
206010039073 rheumatoid arthritis Diseases 0.000 claims description 17
206010009900 Colitis ulcerative Diseases 0.000 claims description 16
201000006704 Ulcerative Colitis Diseases 0.000 claims description 16
208000032839 leukemia Diseases 0.000 claims description 11
206010025323 Lymphomas Diseases 0.000 claims description 8
208000037819 metastatic cancer Diseases 0.000 claims description 6
208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 6
239000002246 antineoplastic agent Substances 0.000 claims description 5
239000003053 toxin Substances 0.000 claims description 4
231100000765 toxin Toxicity 0.000 claims description 4
208000016691 refractory malignant neoplasm Diseases 0.000 claims description 2
125000002345 steroid group Chemical group 0.000 claims 1
108010038498 Interleukin-7 Receptors Proteins 0.000 description 134
210000004027 cell Anatomy 0.000 description 131
102000010782 Interleukin-7 Receptors Human genes 0.000 description 130
230000000694 effects Effects 0.000 description 59
230000014509 gene expression Effects 0.000 description 35
229960003957 dexamethasone Drugs 0.000 description 34
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 34
102000000704 Interleukin-7 Human genes 0.000 description 25
229940100994 interleukin-7 Drugs 0.000 description 25
239000003814 drug Substances 0.000 description 20
229940079593 drug Drugs 0.000 description 15
208000027866 inflammatory disease Diseases 0.000 description 14
208000024891 symptom Diseases 0.000 description 13
238000000034 method Methods 0.000 description 12
210000001744 T-lymphocyte Anatomy 0.000 description 11
230000003247 decreasing effect Effects 0.000 description 11
210000001165 lymph node Anatomy 0.000 description 10
230000004083 survival effect Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
238000002054 transplantation Methods 0.000 description 10
206010027476 Metastases Diseases 0.000 description 9
230000009401 metastasis Effects 0.000 description 9
206010058467 Lung neoplasm malignant Diseases 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
108091027967 Small hairpin RNA Proteins 0.000 description 8
206010003246 arthritis Diseases 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
201000005202 lung cancer Diseases 0.000 description 8
208000020816 lung neoplasm Diseases 0.000 description 8
238000011580 nude mouse model Methods 0.000 description 8
239000004055 small Interfering RNA Substances 0.000 description 8
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
108091012583 BCL2 Proteins 0.000 description 7
208000008771 Lymphadenopathy Diseases 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
230000010261 cell growth Effects 0.000 description 7
239000000562 conjugate Substances 0.000 description 7
210000003414 extremity Anatomy 0.000 description 7
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 7
210000002429 large intestine Anatomy 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
241000699660 Mus musculus Species 0.000 description 6
230000022534 cell killing Effects 0.000 description 6
230000008030 elimination Effects 0.000 description 6
238000003379 elimination reaction Methods 0.000 description 6
208000018555 lymphatic system disease Diseases 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000003472 neutralizing effect Effects 0.000 description 6
239000002504 physiological saline solution Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
210000003462 vein Anatomy 0.000 description 6
230000004580 weight loss Effects 0.000 description 6
TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 5
102000042838 JAK family Human genes 0.000 description 5
108091082332 JAK family Proteins 0.000 description 5
230000004913 activation Effects 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
210000005007 innate immune system Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
108010008165 Etanercept Proteins 0.000 description 4
210000000683 abdominal cavity Anatomy 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229940124599 anti-inflammatory drug Drugs 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000006866 deterioration Effects 0.000 description 4
229960000403 etanercept Drugs 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
208000037843 metastatic solid tumor Diseases 0.000 description 4
230000002265 prevention Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
208000004736 B-Cell Leukemia Diseases 0.000 description 3
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
206010005003 Bladder cancer Diseases 0.000 description 3
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 3
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
230000035508 accumulation Effects 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000001919 adrenal effect Effects 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
208000003747 lymphoid leukemia Diseases 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
239000012528 membrane Substances 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000035790 physiological processes and functions Effects 0.000 description 3
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
238000010186 staining Methods 0.000 description 3
229940037128 systemic glucocorticoids Drugs 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
201000005112 urinary bladder cancer Diseases 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 2
BQQGAGGSEMLWRS-UHFFFAOYSA-N (4-aminophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(N)C=C1 BQQGAGGSEMLWRS-UHFFFAOYSA-N 0.000 description 2
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
206010000830 Acute leukaemia Diseases 0.000 description 2
108010024976 Asparaginase Proteins 0.000 description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
102100038080 B-cell receptor CD22 Human genes 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
238000000018 DNA microarray Methods 0.000 description 2
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
208000007433 Lymphatic Metastasis Diseases 0.000 description 2
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
208000002151 Pleural effusion Diseases 0.000 description 2
208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
206010003230 arteritis Diseases 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
229960002537 betamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
238000010609 cell counting kit-8 assay Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960002173 citrulline Drugs 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
229960003654 desoxycortone Drugs 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
101150007302 dntt gene Proteins 0.000 description 2
230000035622 drinking Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000004744 fore-foot Anatomy 0.000 description 2
230000006870 function Effects 0.000 description 2
230000036732 histological change Effects 0.000 description 2
102000054350 human CHI3L1 Human genes 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
239000006166 lysate Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000002969 morbid Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
210000004910 pleural fluid Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
230000011664 signaling Effects 0.000 description 2
VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
INAUWOVKEZHHDM-PYBHCKQVSA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-(5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl)oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C(OC(C)C1O)CC1N1CCOCC1 INAUWOVKEZHHDM-PYBHCKQVSA-N 0.000 description 1
ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
GSBMEQZETXZGTM-UHFFFAOYSA-N 1H-1,2-benzodiazepine 2,3-dihydro-1H-indole Chemical class N1N=CC=CC2=C1C=CC=C2.N2CCC1=CC=CC=C21 GSBMEQZETXZGTM-UHFFFAOYSA-N 0.000 description 1
YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
101150087690 ACTB gene Proteins 0.000 description 1
206010073485 Abdominal lymphadenopathy Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010055128 Autoimmune neutropenia Diseases 0.000 description 1
206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
208000023514 Barrett esophagus Diseases 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101150018757 CD19 gene Proteins 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
101150066002 GFP gene Proteins 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102100033417 Glucocorticoid receptor Human genes 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
208000008899 Habitual abortion Diseases 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
206010023799 Large intestinal ulcer Diseases 0.000 description 1
208000012309 Linear IgA disease Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
206010036697 Primary hypothyroidism Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000508269 Psidium Species 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
208000000728 Thymus Neoplasms Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
150000004056 anthraquinones Chemical class 0.000 description 1
230000003367 anti-collagen effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
108010044540 auristatin Proteins 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
206010003883 azoospermia Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000981 bystander Effects 0.000 description 1
229940074360 caffeic acid Drugs 0.000 description 1
235000004883 caffeic acid Nutrition 0.000 description 1
229930195731 calicheamicin Natural products 0.000 description 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
229940097217 cardiac glycoside Drugs 0.000 description 1
239000002368 cardiac glycoside Substances 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000004953 colonic tissue Anatomy 0.000 description 1
LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000002247 constant time method Methods 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
229960000648 digitoxin Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
-1 dimethyl sulfene Chemical compound 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
210000003027 ear inner Anatomy 0.000 description 1
230000000235 effect on cancer Effects 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229930013356 epothilone Natural products 0.000 description 1
150000003883 epothilone derivatives Chemical class 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000003811 finger Anatomy 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
210000003194 forelimb Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000002223 garnet Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229950006240 hydrocortisone succinate Drugs 0.000 description 1
VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
125000000879 imine group Chemical group 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
208000002741 leukoplakia Diseases 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000015238 neurotic disease Diseases 0.000 description 1
210000000929 nociceptor Anatomy 0.000 description 1
108091008700 nociceptors Proteins 0.000 description 1
229950006344 nocodazole Drugs 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
208000005368 osteomalacia Diseases 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 description 1
SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000000746 purification Methods 0.000 description 1
YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
239000012925 reference material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000036280 sedation Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000002924 silencing RNA Substances 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229930002534 steroid glycoside Natural products 0.000 description 1
150000008143 steroidal glycosides Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000008961 swelling Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Mycology (AREA)
Orthopedic Medicine & Surgery (AREA)
Microbiology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

TW107106953A 2017-03-03 2018-03-02 抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物 TW201834698A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2017040691		2017-03-03
JP2017-040691		2017-03-03

Publications (1)

Publication Number	Publication Date
TW201834698A true TW201834698A (zh)	2018-10-01

Family

ID=63371345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW107106953A TW201834698A (zh)	2017-03-03	2018-03-02	抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物

Country Status (3)

Country	Link
JP (1)	JPWO2018159808A1 (ja)
TW (1)	TW201834698A (ja)
WO (1)	WO2018159808A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2025089399A1 (ja) *	2023-10-26	2025-05-01	国立研究開発法人国立がん研究センター	インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ）

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20032672A3 (cs) *	2001-04-06	2003-12-17	University Of Bristol	CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
AU2005271113B2 (en) *	2004-08-10	2010-12-09	Cardiff Biologicals Limited	Methods and kit for the prognosis of breast cancer
NO331891B1 (no) *	2007-03-20	2012-04-30	Clavis Pharma Asa	Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
JP2014015396A (ja) *	2010-10-29	2014-01-30	Perseus Proteomics Inc	高い親和性を有する抗ｃｄｈ３抗体

2018
- 2018-03-02 JP JP2019503147A patent/JPWO2018159808A1/ja active Pending
- 2018-03-02 WO PCT/JP2018/007985 patent/WO2018159808A1/ja not_active Ceased
- 2018-03-02 TW TW107106953A patent/TW201834698A/zh unknown

Also Published As

Publication number	Publication date
JPWO2018159808A1 (ja)	2019-12-26
WO2018159808A1 (ja)	2018-09-07

Publication	Publication Date	Title
CN111936164B (zh)	2024-09-17	癌的治疗和/或预防用药物组合物
Afar et al.	2004	Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer
EP3565596A1 (en)	2019-11-13	Methods and compositions relating to anti-chi3l1 antibody reagents
JP7473474B2 (ja)	2024-04-23	抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
KR20160099725A (ko)	2016-08-22	자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
EP3590534A1 (en)	2020-01-08	Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
AU2020252119A1 (en)	2021-10-07	Interleukin-2 variants with modified biological activity
US20250154250A1 (en)	2025-05-15	Ceacam5 adc-anti-pd1/pd-l1 combination therapy
Huber-Ruano et al.	2017	An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages
CN115052632B (zh)	2025-01-14	靶向多肽-药物缀合物及其用途
Wang et al.	2024	A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus
WO2021228044A1 (en)	2021-11-18	Drug conjugates containing alpha-enolase antibodies and uses thereof
WO2022242692A1 (en)	2022-11-24	Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer
EP4101438B1 (en)	2025-04-16	Combination treatment of a saponin agent and an anthelminitic agent against cancer
TW201834698A (zh)	2018-10-01	抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物
CN118401258A (zh)	2024-07-26	一种亲和力改善的抗体-药物偶联物、其制备方法及应用
Jaime-Ramirez et al.	2016	NK cell–mediated antitumor effects of a folate-conjugated immunoglobulin are enhanced by cytokines
WO2017023760A1 (en)	2017-02-09	Extracellular drug conjugates targeting cd20
WO2025077814A1 (en)	2025-04-17	An antibody-drug conjugate treatment of cancer
WO2024194455A1 (en)	2024-09-26	CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
CN120860240A (zh)	2025-10-31	Icam1或其编码基因在制备炎性乳腺癌治疗或诊断产品中的用途
TW202440169A (zh)	2024-10-16	抗體-藥物結合物與dnmt抑制劑之組合
CN117018212A (zh)	2023-11-10	PD-L1-GEMs在制备膀胱癌靶向及免疫联合治疗药物中的应用
WO2013067581A1 (en)	2013-05-16	Cancer treatment
Dransfield et al.	2016	Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo